Predicting clot and bleeding risk in kidney disease patients after a heart attack
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Kidney & urinary clinical trials.
This trial tests whether a blood test looking at platelets and tiny cell particles can help predict future blood clots or bleeding in people who have both chronic kidney disease and a recent heart attack. The goal is to improve treatment safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 89 years old.
- You have chronic kidney disease (stage 3 or higher, with an eGFR of 78 or less).
- You have had a recent heart attack (either non‑ST‑elevation or ST‑elevation) and are scheduled for a procedure to open blocked arteries.
- If you are a woman of childbearing age, you must use reliable birth control or be postmenopausal.
- You are not taking blood‑thinning medications (anticoagulants) and have no other major bleeding risks.
- You do not have any of the following: insulin‑treated diabetes, active cancer, autoimmune disease, or a history of stroke within the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for new markers in blood or urine that may help explain heart (cardiovascular) risk in people with chronic kidney disease. It may help doctors better predict risk, especially in those not yet on dialysis.
This trial uses a special ultrasound camera inside the heart's arteries to guide stent placement for people with chronic kidney disease. The goal is to see if this approach improves outcomes compared to standard methods.
This study is looking at a protein in the blood (renalase) and how it relates to blockages in tiny blood vessels after a heart attack. Researchers want to see if this protein can help predict recovery, which could lead to better treatments.
This study looks at whether the time from a heart attack (STEMI) until the procedure to open the blocked artery affects the risk of kidney damage from the contrast dye used during the procedure. It may help doctors predict and prevent kidney problems in heart attack patients.
This study looks at the best length of anti-platelet medicine (which helps prevent stent clots) after a new type of heart stent. It specifically focuses on people with advanced chronic kidney disease, where bleeding and clot risks can be higher.
This study examines new blood markers to predict blood clot and bleeding risks in patients with heart disease taking blood thinners. Understanding these markers may help doctors better predict complications and adjust treatment for individual patients.
Hear when a new Chronic Kidney Disease stage3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.